It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
{{output}}
Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evid... ...
